Skip to content

GalaFlex Mesh in Facelift

GalaFlex Mesh in Facelift

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02053831
Enrollment
15
Registered
2014-02-04
Start date
2011-11-30
Completion date
2014-06-30
Last updated
2023-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial Musculoaponeurotic System (SMAS) Procedure

Keywords

plastic surgery

Brief summary

In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area. GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.

Interventions

None listed

Sponsors

Tepha, Inc.
CollaboratorINDUSTRY
C. R. Bard
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.) * Be at least 21 years of age. * Be willing and able to comply with the requirements of the protocol. * Be willing to refrain from participating in any other investigational interventional study while enrolled in this study. * Female subjects must have a negative pregnancy test within the last 24 hours timeline and have no intentions of becoming pregnant during participation in the study, or be sterilized.

Exclusion criteria

* Subject is unwilling or unable to give written consent to participate in the investigation or unable to comply with the requirements of the protocol. * Subject has known severe allergies manifested by a history of anaphylaxis, or history or presence of severe multiple allergies. * Subject has any serious skin disease, e.g., Eczema and psoriasis of the face, severe rosacea, scleroderma, local infections and severe acne. * Subjects has diabetes, coagulation disorders, connective tissue disorders, lipodystrophy, or other serious systemic disease. * Active herpes labialis * Subject is infected with HIV and/or received or may receive immunosuppressive therapy over the course of the study (such as rheumatoid arthritis). * Received any experimental drug or device within the previous three months. * Known alcohol or drug abuser. * Female subject who is pregnant or lactating or intending to become pregnant during the period of the study, or who would not use an adequate method of contraception (contraceptive pill, intra-uterine device) for the duration of the study. * Possesses any psychological condition, or is under treatment for any condition which, in the opinion of the Investigator and/or consulting physicians(s),would constitute an unwarranted risk. * Presents with severe jowling or severe cervical skin redundancy. * Subject is currently a smoker or is a prior smoker who quit in the last 12 months. * Active abscess or infection * Currently involved with claims for, or is accepting, workers compensation * Currently engaged in medical malpractice litigation.

Design outcomes

Primary

MeasureTime frameDescription
Physician Satisfaction1 yearInvestigator satisfaction will be judged by ease of product use, successful reinforcement, and total time for procedure to be completed.

Secondary

MeasureTime frameDescription
Patient Satisfaction1 yearPatient satisfaction will be judged by the difference between pre- and post-surgery answers to Quality of Life questionnaires.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026